Evidence map›Paper›PMID 38420407›Full record

ArticleHeliyon2024

The global landscape of immune-derived lncRNA signature in colorectal cancer.

Mengying Zhang, Yifei Wu, Jingyi Mou, Yang Yao, Pengbo Wen, Xin Liu, Shipeng Shang, Xingxing Kang, Jiaqi Tian, Yan Liu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. LncRNATranslational cancer research · 2024
    Article
  4. The roles of lncRNATranslational cancer research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mengying ZhangSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yifei WuSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jingyi MouDepartment of Clinical Medicine, School of 1st Clinical Medicine, Xuzhou Medical University, Xuzhou, China.
Yang YaoSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Pengbo WenSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xin LiuSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Shipeng ShangSchool of Basic Medicine, Qingdao University, Qingdao, China.
Xingxing KangSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jiaqi TianSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yan LiuSchool of Life Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Enhui LvSchool of Medical Information and Engineering, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Liang WangLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China.
Xuzhou Medical College · CNEdith Cowan University · AUQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a highly heterogeneous cancer. This heterogeneity has an impact on the efficacy of immunotherapy. Long noncoding RNAs (lncRNAs) have been found to play regulatory functions in cancer immunity. However, the global landscape of immune-derived lncRNA signatures has not yet been explored in colorectal cancer.

methodsIn this study, we applied DESeq2 to identify differentially expressed lncRNAs in colon cancer. Next, we performed an integrative analysis to globally identify immune-driven lncRNA markers in CRC, including immune-associated pathways, tumor immunogenomic features, tumor-infiltrating immune cells, immune checkpoints, microsatellite instability (MSI) and tumor mutation burden (TMB).

resultsWe also identified dysregulated lncRNAs, such as LINC01354 and LINC02257, and their clinical relevance in CRC. Our findings revealed that the differentially expressed lncRNAs were closely associated with immune pathways. In addition, we found that RP11-354P11.3 and RP11-545G3.1 had the highest association with the immunogenomic signature. As a result, these signatures could serve as markers to assess immunogenomic activity in CRC. Among the immune cells, resting mast cells and M0 macrophages had the highest association with lncRNAs in CRC. The AC006129.2 gene was significantly associated with several immune checkpoints, for example, programmed cell death protein 1 (PD-1) and B and T lymphocyte attenuator (BTLA). Therefore, the AC006129.2 gene could be targeted to regulate the condition of immune cells or immune checkpoints to enhance the efficacy of immunotherapy in CRC patients. Finally, we identified 15 immune-related lncRNA-generated open reading frames (ORFs) corresponding to 15 cancer immune epitopes.

conclusionIn conclusion, we provided a genome-wide immune-driven lncRNA signature for CRC that might provide new insights into clinical applications and immunotherapy.

Indexed as

Colorectal cancerImmune-derived lncRNAImmune epitopesImmune-related pathwaysImmunotherapy

Identifiers

PMID38420407
PMCPMC10900961
OpenAlexW4391691603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.